drugset / Trial / NCT00888862

Desvenlafaxine Succinate (DVS) for Major Depressive Disorder (MDD) in Midlife Men and Women

NCT00888862

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to characterize a range of brain activation symptoms associated with depression and response to treatment in midlife men and women with MDD, using MRI and functional MRI. Moreover, in the female sub-group, the investigators will examine whether these brain activation symptoms are related to menopausal symptoms (i.e., hot flashes and night sweats). Also, assessing brain activation before and after the treatment might help to uncover some mechanisms associated with the pathophysiology of depression and menopause.

Timeline

Start
2009-06
Primary completion
2012-06
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Desvenlafaxine Other / unclassified 50 mg
Subject Desvenlafaxine Other / unclassified 100 mg